ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Actinium Pharmaceuticals, Inc. for potential violations of securities laws related to misleading statements and failure to disclose important information to investors [1] Group 1: Company Overview - Actinium Pharmaceuticals, Inc. is focused on developing treatments for acute myeloid leukemia, specifically through its product Iomab-B [1] - The company announced a regulatory update regarding its Biologics License Application (BLA) filing for Iomab-B on August 5, 2024 [1] Group 2: Regulatory and Market Impact - The FDA has determined that the Phase 3 SIERRA trial is insufficient to support a BLA filing for Iomab-B, despite the trial meeting its statistically significant primary endpoint [1] - Following this announcement, Actinium's shares experienced a significant decline, falling by almost 60% on the same day [1]